Skip to main content
. 2016 Mar;13(3):342–349. doi: 10.1513/AnnalsATS.201509-631OC

Table 2.

The Markov-chain cyst-transition (from TLC to RV) matrix analysis

Cyst Volume Definitions Cyst Size Transition (from TLC to RV) Number of Cysts Transitioning in Size during Expiration (from TLC to RV)
P Values for Placebo vs. Sirolimus
Placebo (n = 14)
Sirolimus (n = 17)
Baseline, % (SD) 12 Mo, % (SD) Baseline, % (SD) 12 Mo, % (SD)
Threshold 1 (small, <50 ml; medium, <200 ml and >50 ml; large, >200 ml) Medium to small 32 (19) 24 (17) 18 (22) 18 (20) 0.02
Large to medium 0 (0) 0 (0) 0 (2) 0 (1) ns
Large to small 54 (27) 46 (27) 30 (31) 34 (29) 0.02
Threshold 2 (small, <20 ml; medium, <100 ml and >20 ml; large, >100 ml) Medium to small 13 (14) 8 (10) 7 (10) 5 (8) ns
Large to medium 1 (3) 2 (4) 0 (1) 1 (2) ns
Large to small 46 (24) 37 (22) 25 (28) 27 (25) 0.005
Threshold 3 (small, <20 mm3; medium, <50 ml and >20 ml; large, >50 ml) Medium to small 7 (11) 4 (6) 3 (6) 2 (5) ns
Large to medium 2 (3) 3 (4) 2 (3) 3 (3) ns
Large to small 36 (20) 28 (18) 20 (23) 20 (21) 0.006

Definition of abbreviations: ns = not significant; RV = residual volume; SD = standard deviation; TLC = total lung capacity.

Data are presented as the percentage of LAM cysts transitioning in volume from TLC to RV at baseline and 12 months. Volume categories were arbitrarily defined on the basis of thresholds listed in the left column. The differences from baseline to 12 months in the numbers of cysts transitioning between volume categories during expiration were then compared between the placebo and sirolimus groups.